BioNTech SE

BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches designed to address hard-to-treat tumors. BioNTech also develops vaccine candidates and other immune-modulating treatments aimed at preventing or managing serious infectious diseases. Its work spans multiple platforms, including mRNA, protein-based therapies, and next-generation immunomodulators, reflecting a broad research and development base. BioNTech SE serves a central role in the biopharmaceutical market by advancing precision medicine approaches that combine molecular science with clinical development, supporting both preventative and therapeutic applications across global healthcare markets.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Ugur Sahin M.D.

Employees

6,772

Headquarters

Mainz, MI, Germany

Website

www.biontech.de